Physician profile
Peter M Partee
NPI 1912945841
$17,752.32
in general payments reported to CMS, 2019-2025
39 companies · $8,664 in 2025
The $8,664 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $215 · 2021: $178 · 2022: $1,198 · 2023: $1,726 · 2024: $5,229 · 2025: $8,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,943 · Food and Beverage: $6,047 · Travel and Lodging: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,943.00 |
| Food and Beverage | $6,046.84 |
| Travel and Lodging | $629.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $10,140.44 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbvie INC. | $1,494.92 | 2022-2025 | |
| Novo Nordisk INC | $848.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $738.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.28 | 2020-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $448.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $447.88 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $413.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $329.84 | 2019-2025 | |
| Abbott Laboratories | $236.74 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $230.54 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $218.11 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.20 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $173.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $156.94 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.34 | 2019-2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $120.15 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $118.55 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $114.95 | 2019-2023 | |
| Corcept Therapeutics | $94.87 | 2024-2025 | Korlym |
| Daiichi Sankyo INC. | $87.26 | 2019-2024 | Injectafer |
| Allergan, INC. | $74.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $73.28 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Lundbeck LLC | $62.25 | 2024-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $61.46 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $43.65 | 2024 | Hetlioz, Fanapt |
| Abiomed | $36.40 | 2024-2025 | Impella |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.31 | 2022 | |
| Medtronic, INC. | $25.65 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $24.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.86 | 2022 | |
| Inari Medical, INC. | $22.83 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tris Pharma INC | $21.72 | 2025 | Dyanavel Xr |
| Amarin Pharma, INC. | $16.75 | 2019 | |
| Esperion Therapeutics, INC. | $14.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.31 | 2024 | Quviviq |
| Promius Pharma LLC | $12.18 | 2019 | |
| Organon LLC | $8.46 | 2025 | Nexplanon |
| Dynavax Technologies Corporation | $6.50 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Partee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.